Skip to content

Kodiak Sciences Inc KOD Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$163.1M+169%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$294K-93.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$0-100%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.21M+219%
Vera Therapeutics logo
Vera TherapeuticsVERA
$3.94M+157%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$1.07M

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's stock issuance proceeds?
Kodiak Sciences Inc (KOD) reported stock issuance proceeds of $922K in Q1 2026.
How has Kodiak Sciences Inc's stock issuance proceeds changed year-over-year?
Kodiak Sciences Inc's stock issuance proceeds increased by 643.5% year-over-year, from $124K to $922K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.